N-heterocyclic inhibitors of TNF-α expression
US7479495B2 · kind B2 · utility
11Cited by
23References
32Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 2, 2005 |
| Grant date | Jan 20, 2009 |
| Priority date | — |
| Expiry date | Sep 21, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I:Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.